Floatz logo

XENON

Cerebrovascular Accident

Stanford UniversitySmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Cerebrovascular Accident cohort.

Asset / SponsorPhaseRating
Aggrenox
Boehringer Ingelheim
Phase 4BBB
ADVICOR COMPONENT NIACIN
Axio Research. LLC
Phase 4BB
Benserazide
University Hospital Muenster
Phase 4BB
CANDESARTAN
Population Health Research Institute
Phase 4BB
VALSARTAN
Stanford University
Phase 4BB

View all 35 →

Same molecule, other indications

XENON is also rated in:

cystic fibrosisDormant
BB
Indicative ·
65 / 100
View asset →
asthmaDormant
B
Indicative ·
63 / 100
View asset →
pulmonary fibrosisDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →